Identification

Name
Resveratrol
Accession Number
DB02709  (EXPT02968)
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as two structural isomers: cis-(Z) and trans-(E), with the trans-isomer shown in the top image. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.

Structure
Thumb
Synonyms
  • (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
  • (E)-resveratrol
  • 3,4',5-trihydroxy-trans-stilbene
  • 3,4',5-trihydroxystilbene
  • 3,5,4'-trihydroxystilbene
  • 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
  • trans-resveratrol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Co-VeratrolResveratrol (400 mg/mg) + Folic Acid (.8 mg/mg) + Methylcobalamin (5 mg/mg) + Ubiquinol (200 mg/mg)CapsuleOralHome Aide Diganostics, Inc.2015-08-01Not applicableUs
Categories
UNII
Q369O8926L
CAS number
501-36-0
Weight
Average: 228.2433
Monoisotopic: 228.07864425
Chemical Formula
C14H12O3
InChI Key
LUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChI
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
IUPAC Name
5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
SMILES
OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1

Pharmacology

Indication

Being investigated for the treatment of Herpes labialis infections (cold sores).

Structured Indications
Not Available
Pharmacodynamics

Resveratrol, a phytoalexin, has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, reversible manner, although this is only one of its many pharmaceutical properties. In some countries where there is higher consumption of red wine, there appears to be a lower incidence of heart disease. Other benefits of resveratrol include its anti-inflammatory and antioxidant effects. In preclinical studies, Resveratrol has been found to have potential anticancer properties.

Mechanism of action

Resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914].

TargetActionsOrganism
URibosyldihydronicotinamide dehydrogenase [quinone]Not AvailableHuman
UCasein kinase II subunit alphaNot AvailableHuman
UProstaglandin G/H synthase 1
inhibitor
Human
UProstaglandin G/H synthase 2
inhibitor
Human
UArachidonate 15-lipoxygenaseNot AvailableHuman
UArachidonate 5-lipoxygenaseNot AvailableHuman
UAryl hydrocarbon receptorNot AvailableHuman
UPhosphatidylinositol 4-kinase type 2-betaNot AvailableHuman
UIntegrin alpha-5Not AvailableHuman
UIntegrin beta-3Not AvailableHuman
UAmyloid beta A4 proteinNot AvailableHuman
UAlpha-synucleinNot AvailableHuman
UEstrogen receptor alphaNot AvailableHuman
UMelatonin receptor type 1ANot AvailableHuman
UMelatonin receptor type 1BNot AvailableHuman
UC-type lectin domain family 14 member ANot AvailableHuman
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
UNuclear receptor subfamily 1 group I member 3Not AvailableHuman
USolute carrier family 2, facilitated glucose transporter member 1Not AvailableHuman
UCarbonyl reductase [NADPH] 1
inhibitor
Human
UPeroxisome proliferator-activated receptor alphaNot AvailableHuman
UPeroxisome proliferator-activated receptor gammaNot AvailableHuman
URAC-alpha serine/threonine-protein kinase
inhibitor
Human
UFar upstream element-binding protein 2Not AvailableHuman
UTyrosine--tRNA ligase, cytoplasmic
inhibitor
Human
Absorption

High absorption but very low bioavailability.

Volume of distribution
Not Available
Protein binding

Strong affinity towards protein binding.

Metabolism

Hepatic. Rapidly metabolized and excreted.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 5-androstenedione.Experimental, Illicit
AbciximabResveratrol may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Resveratrol can be increased when it is combined with Abiraterone.Approved
AcebutololResveratrol may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Acemetacin.Approved
AcenocoumarolResveratrol may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Resveratrol.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Resveratrol.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinResveratrol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Resveratrol.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid.Approved
AliskirenResveratrol may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aloxiprin.Experimental
AlprenololResveratrol may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Resveratrol.Approved, Investigational
AlteplaseResveratrol may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Resveratrol may increase the anticoagulant activities of ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Amcinonide.Approved
AmikacinResveratrol may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideResveratrol may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aminosalicylic Acid.Approved
AmrubicinResveratrol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideResveratrol may increase the anticoagulant activities of Anagrelide.Approved
AncrodResveratrol may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Resveratrol is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Anisodamine.Investigational
AnistreplaseResveratrol may increase the anticoagulant activities of Anistreplase.Approved
annamycinResveratrol may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.Approved
Antithrombin III humanResveratrol may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apocynin.Investigational
ApramycinResveratrol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apremilast.Approved, Investigational
ArbekacinResveratrol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinResveratrol may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanResveratrol may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololResveratrol may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AstaxanthinResveratrol may increase the anticoagulant activities of Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Atamestane.Investigational
AtenololResveratrol may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol.Approved
AzithromycinThe metabolism of Resveratrol can be decreased when combined with Azithromycin.Approved
BalsalazideResveratrol may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BatroxobinResveratrol may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminResveratrol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololResveratrol may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinResveratrol may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinResveratrol may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Resveratrol.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol.Approved
BenorilateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Resveratrol.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Betamethasone.Approved, Vet Approved
BetaxololResveratrol may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
BevantololResveratrol may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Resveratrol.Approved, Investigational
BisoprololResveratrol may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinResveratrol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololResveratrol may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Resveratrol can be decreased when combined with Bortezomib.Approved, Investigational
BrinaseResveratrol may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Resveratrol.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bucillamine.Investigational
BucindololResveratrol may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bufexamac.Experimental
BuflomedilResveratrol may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolResveratrol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bumadizone.Experimental
BumetanideResveratrol may decrease the diuretic activities of Bumetanide.Approved
BupranololResveratrol may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideResveratrol may increase the antiplatelet activities of Butylphthalide.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Resveratrol.Approved
CaffeineThe metabolism of Resveratrol can be decreased when combined with Caffeine.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Resveratrol.Experimental
CangrelorResveratrol may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Resveratrol.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Resveratrol is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Resveratrol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol.Approved, Vet Approved, Withdrawn
CarteololResveratrol may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolResveratrol may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol.Experimental
CeliprololResveratrol may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Resveratrol.Withdrawn
CertoparinResveratrol may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Resveratrol.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Resveratrol.Approved
CilostazolResveratrol may increase the anticoagulant activities of Cilostazol.Approved
CinoxacinResveratrol may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Resveratrol can be decreased when combined with Citalopram.Approved
Citric AcidResveratrol may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clonixin.Approved
ClopidogrelResveratrol may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Resveratrol.Vet Approved
CloranololResveratrol may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenResveratrol may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneResveratrol may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Resveratrol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Resveratrol is combined with Collagenase clostridium histolyticum.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Resveratrol is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Resveratrol.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
CyclosporineResveratrol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Resveratrol.Experimental
Cyproterone acetateThe serum concentration of Resveratrol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Resveratrol is combined with D-Limonene.Investigational
Dabigatran etexilateResveratrol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinResveratrol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidResveratrol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanResveratrol may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Resveratrol.Approved, Investigational
DaunorubicinResveratrol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox.Approved, Investigational
DefibrotideResveratrol may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Resveratrol.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Resveratrol is combined with dersalazine.Investigational
DesirudinResveratrol may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Resveratrol.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.Approved
DesmoteplaseResveratrol may increase the anticoagulant activities of Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Resveratrol.Approved, Investigational
DextranResveratrol may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Resveratrol may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Resveratrol may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Resveratrol may increase the anticoagulant activities of Dextran 75.Approved
DibekacinResveratrol may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Resveratrol.Approved, Vet Approved
DicoumarolResveratrol may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Resveratrol is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Resveratrol.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Resveratrol.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Resveratrol.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Resveratrol.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Resveratrol.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Resveratrol.Approved
DihydrostreptomycinResveratrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Resveratrol.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Resveratrol.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Resveratrol.Approved
DiphenadioneResveratrol may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleResveratrol may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleResveratrol may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.Approved, Investigational
DosulepinThe metabolism of Resveratrol can be decreased when combined with Dosulepin.Approved
DoxorubicinResveratrol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneResveratrol may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaResveratrol may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Resveratrol is combined with E-6201.Investigational
Edetic AcidResveratrol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanResveratrol may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Resveratrol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Resveratrol.Approved
EnoxacinResveratrol may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinResveratrol may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Resveratrol.Experimental
EpanololResveratrol may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of Resveratrol.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Resveratrol is combined with Epirizole.Approved
EpirubicinResveratrol may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneResveratrol may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinResveratrol may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineResveratrol may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Resveratrol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.Approved
EptifibatideResveratrol may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Resveratrol is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Equilin.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Resveratrol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Resveratrol.Approved
EsmololResveratrol may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone sulfate.Approved
Etacrynic acidResveratrol may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ethenzamide.Experimental
Ethyl biscoumacetateResveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etofenamate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Resveratrol is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Resveratrol.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Feprazone.Experimental
Ferulic acidResveratrol may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinResveratrol may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Resveratrol.Approved, Investigational
FleroxacinResveratrol may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Resveratrol.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fludrocortisone.Approved
FluindioneResveratrol may increase the anticoagulant activities of Fluindione.Investigational
FlumequineResveratrol may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Resveratrol.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Resveratrol.Approved
FluvoxamineThe metabolism of Resveratrol can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Resveratrol.Approved, Nutraceutical, Vet Approved
FondaparinuxResveratrol may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumResveratrol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Resveratrol.Approved
FramycetinResveratrol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideResveratrol may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateResveratrol may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinResveratrol may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinResveratrol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Resveratrol.Approved, Withdrawn
GemifloxacinResveratrol may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinResveratrol may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinResveratrol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AResveratrol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GitoformateGitoformate may decrease the cardiotoxic activities of Resveratrol.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Resveratrol.Approved
GPX-150Resveratrol may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinResveratrol may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Resveratrol is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Resveratrol is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Hemoglobin crosfumaril.Experimental
HeparinResveratrol may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineResveratrol may increase the anticoagulant activities of Higenamine.Investigational
HydralazineResveratrol may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol.Approved, Investigational
HydroxytyrosolResveratrol may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Hygromycin BResveratrol may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Resveratrol.Approved
IbudilastResveratrol may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Resveratrol.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Resveratrol is combined with Icatibant.Approved
Icosapent ethylResveratrol may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinResveratrol may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxResveratrol may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilResveratrol may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanResveratrol may increase the antiplatelet activities of Ifetroban.Investigational
IloprostIloprost may increase the antiplatelet activities of Resveratrol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Resveratrol.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.Approved
IndenololResveratrol may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenResveratrol may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Indoprofen.Withdrawn
INNO-206Resveratrol may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.Approved, Investigational
IsepamicinResveratrol may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Resveratrol is combined with Istaroxime.Investigational
KanamycinResveratrol may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Kebuzone.Experimental
KetanserinResveratrol may increase the antiplatelet activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Resveratrol.Approved
LabetalolResveratrol may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Resveratrol.Experimental
LandiololResveratrol may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Resveratrol.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Resveratrol.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Resveratrol.Approved, Investigational
LepirudinResveratrol may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanResveratrol may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololResveratrol may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinResveratrol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Resveratrol can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostLimaprost may increase the antiplatelet activities of Resveratrol.Approved, Investigational
LinsidomineResveratrol may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Resveratrol.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lisofylline.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Resveratrol.Approved, Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Resveratrol.Approved
LobeglitazoneThe metabolism of Resveratrol can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Resveratrol.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Resveratrol.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Resveratrol.Vet Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Resveratrol.Illicit, Investigational, Withdrawn
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Resveratrol is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol.Approved
MelagatranResveratrol may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.Approved, Vet Approved
MepindololResveratrol may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Resveratrol is combined with Metamizole.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Resveratrol.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Resveratrol.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Resveratrol.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Methylprednisolone.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Resveratrol.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Resveratrol.Experimental
MetipranololResveratrol may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.Approved
MetoprololResveratrol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideResveratrol may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Resveratrol.Experimental
MexiletineThe metabolism of Resveratrol can be decreased when combined with Mexiletine.Approved
MicronomicinResveratrol may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Resveratrol can be decreased when combined with Midostaurin.Approved
MilrinoneMilrinone may increase the antiplatelet activities of Resveratrol.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Resveratrol.Approved
MizoribineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Resveratrol.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Resveratrol.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.Approved
NadololResveratrol may decrease the antihypertensive activities of Nadolol.Approved
NadroparinResveratrol may increase the anticoagulant activities of Nadroparin.Approved
NafamostatResveratrol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Resveratrol.Approved
NaftopidilResveratrol may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidResveratrol may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Resveratrol.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 1022.Investigational
NeamineResveratrol may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinResveratrol may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinResveratrol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nepafenac.Approved
NetilmicinResveratrol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NevirapineThe metabolism of Resveratrol can be decreased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Resveratrol.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nitroaspirin.Investigational
NorfloxacinResveratrol may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Resveratrol.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.Approved
OlsalazineResveratrol may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Resveratrol.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Resveratrol.Approved, Nutraceutical
OrgoteinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Resveratrol can be decreased when it is combined with Osimertinib.Approved
OtamixabanResveratrol may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Resveratrol.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.Approved
Oxolinic acidResveratrol may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololResveratrol may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oxyphenbutazone.Approved, Withdrawn
OzagrelResveratrol may increase the anticoagulant activities of Ozagrel.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Paramethasone.Approved
ParnaparinResveratrol may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParomomycinResveratrol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Parthenolide.Investigational
PazufloxacinResveratrol may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinResveratrol may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololResveratrol may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Resveratrol.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Resveratrol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Resveratrol.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Resveratrol.Experimental
PhenindioneResveratrol may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonResveratrol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol.Approved, Vet Approved
PicotamideResveratrol may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.Approved, Investigational
PindololResveratrol may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidResveratrol may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinResveratrol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideResveratrol may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pirfenidone.Approved, Investigational
Piromidic acidResveratrol may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Resveratrol.Approved
PlazomicinResveratrol may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinResveratrol may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Resveratrol.Approved
PractololResveratrol may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Resveratrol.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone sulfate.Investigational
PrasugrelResveratrol may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Resveratrol.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Resveratrol can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Propacetamol.Approved, Investigational
PropranololResveratrol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Resveratrol.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Resveratrol.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Resveratrol.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Resveratrol.Vet Approved
Protein CResveratrol may increase the anticoagulant activities of Protein C.Approved
Protein S humanResveratrol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeResveratrol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinResveratrol may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Resveratrol is combined with PTC299.Investigational
PuromycinResveratrol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Resveratrol.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol.Approved
RamatrobanResveratrol may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Resveratrol.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Resveratrol.Approved
ReteplaseResveratrol may increase the anticoagulant activities of Reteplase.Approved
ReviparinResveratrol may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinResveratrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Resveratrol.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.Approved, Investigational
RivaroxabanResveratrol may increase the anticoagulant activities of Rivaroxaban.Approved
RopiniroleThe metabolism of Resveratrol can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneResveratrol may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinResveratrol may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Resveratrol.Approved
RufloxacinResveratrol may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinResveratrol may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Resveratrol.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Resveratrol.Investigational
SarpogrelateResveratrol may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseResveratrol may increase the anticoagulant activities of Saruplase.Experimental
SelexipagResveratrol may increase the anticoagulant activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Resveratrol is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Resveratrol is combined with Serrapeptase.Investigational
SevofluraneSevoflurane may increase the antiplatelet activities of Resveratrol.Approved, Vet Approved
SimeprevirThe metabolism of Resveratrol can be decreased when combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Resveratrol.Approved
SisomicinResveratrol may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinResveratrol may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Resveratrol.Approved
SotalolResveratrol may decrease the antihypertensive activities of Sotalol.Approved
SP1049CResveratrol may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinResveratrol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinResveratrol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Resveratrol.Approved
SpironolactoneResveratrol may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Resveratrol is combined with SRT501.Investigational
StreptokinaseResveratrol may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinResveratrol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinResveratrol may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Resveratrol.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Resveratrol.Approved
SulodexideResveratrol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Resveratrol.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Suxibuzone.Experimental
TacrolimusResveratrol may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Resveratrol.Approved
TalinololResveratrol may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Resveratrol.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Resveratrol.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.Approved, Investigational
TemafloxacinResveratrol may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Resveratrol.Experimental, Investigational
TenecteplaseResveratrol may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tepoxalin.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Resveratrol.Experimental
TeriflunomideThe serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide.Approved
TertatololResveratrol may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneResveratrol may increase the antiplatelet activities of Tesmilifene.Investigational
TheophyllineThe metabolism of Resveratrol can be decreased when combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.Approved
TicagrelorResveratrol may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineThe metabolism of Resveratrol can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololResveratrol may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tinoridine.Investigational
TinzaparinResveratrol may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolResveratrol may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Resveratrol.Approved, Investigational
TirofibanResveratrol may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tixocortol.Approved
TobramycinResveratrol may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.Approved
TorasemideResveratrol may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Resveratrol.Approved
TranilastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tranilast.Approved, Investigational
TrapidilResveratrol may increase the antiplatelet activities of Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Triamcinolone.Approved, Vet Approved
TriamtereneResveratrol may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
TriflusalResveratrol may increase the anticoagulant activities of Triflusal.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Triptolide.Investigational
TrovafloxacinResveratrol may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinResveratrol may increase the anticoagulant activities of Troxerutin.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Resveratrol.Approved, Experimental
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Resveratrol.Approved
UrokinaseResveratrol may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValrubicinResveratrol may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Resveratrol.Approved
VemurafenibThe serum concentration of Resveratrol can be increased when it is combined with Vemurafenib.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Resveratrol.Approved, Nutraceutical, Vet Approved
VorapaxarResveratrol may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinResveratrol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranResveratrol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Resveratrol.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Resveratrol.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinResveratrol may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinResveratrol may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZucapsaicinThe metabolism of Resveratrol can be decreased when combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Philippe Jeandet, Roger Bessis, Marielle Adrian, Jean-Claude Yvin, Jean-Marie Joubert, "Use of aluminium chloride as a resveratrol synthesis elicitor." U.S. Patent US6080701, issued August, 1991.

US6080701
General References
  1. Farina A, Ferranti C, Marra C: An improved synthesis of resveratrol. Nat Prod Res. 2006 Mar;20(3):247-52. [PubMed:16401555]
  2. Renaud S, Ruf JC: The French paradox: vegetables or wine. Circulation. 1994 Dec;90(6):3118-9. [PubMed:7994864]
  3. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB: An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002 Jan 30;50(3):431-5. [PubMed:11804508]
  4. Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J, van Breemen RB: Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003 Sep 24;51(20):5867-70. [PubMed:13129286]
  5. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27. [PubMed:15333514]
  6. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M: Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol. 2008 Feb 1;75(3):677-87. Epub 2007 Sep 18. [PubMed:17959154]
  7. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL: Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. [PubMed:10551373]
  8. N' soukpoe-Kossi CN, St-Louis C, Beauregard M, Subirade M, Carpentier R, Hotchandani S, Tajmir-Riahi HA: Resveratrol binding to human serum albumin. J Biomol Struct Dyn. 2006 Dec;24(3):277-83. [PubMed:17054386]
External Links
Human Metabolome Database
HMDB03747
KEGG Compound
C03582
PubChem Compound
445154
PubChem Substance
46504705
ChemSpider
392875
BindingDB
23926
ChEBI
45713
ChEMBL
CHEMBL165
Therapeutic Targets Database
DNC001205
PharmGKB
PA165291838
HET
STL
Wikipedia
Resveratrol
PDB Entries
1cgz / 1dvs / 1sg0 / 1u0w / 1z1f / 2jiz / 2l98 / 2ydx / 3ckl / 3fts
show 13 more
MSDS
Download (16.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentDiabetic Nephropathies1
1Active Not RecruitingTreatmentDiastolic Heart Failure / Heart Failure With Preserved Ejection Fraction (HFpEF) / Hypertensive / Hypertensive Heart Disease / Oxidative Stress1
1CompletedNot AvailableMemory1
1CompletedBasic ScienceHealthy, no Evidence of Disease1
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedPreventionHealthy, no Evidence of Disease1
1CompletedPreventionUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Stage I Colon Cancer / Stage I Rectal Cancer / Stage II Colon Cancer / Stage II Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer1
1CompletedTreatmentCancers / Malignant Neoplasm of Colon1
1CompletedTreatmentParkinson's Disease (PD)4
1, 2CompletedTreatmentFriedreich's Ataxia1
2CompletedBasic ScienceDyslipidemias / Insulin Resistance1
2CompletedBasic ScienceSedentary Lifestyle1
2CompletedPreventionSchizophrenic Disorders1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentBMI >30 kg/m2 / Diabetes1
2CompletedTreatmentMetabolic Syndromes1
2Not Yet RecruitingTreatmentLymphangioleiomyomatosis1
2RecruitingSupportive CareMitochondrial Function / Physical Function1
2RecruitingTreatmentAging1
2RecruitingTreatmentType 2 Diabetes Mellitus1
2Unknown StatusTreatmentFollicular Lymphoma (FL)1
2Unknown StatusTreatmentInsulin Resistance / Type 2 Diabetes Mellitus1
2WithdrawnTreatmentInsulin Resistance1
3Enrolling by InvitationBasic ScienceMetabolic Syndromes1
3Not Yet RecruitingSupportive CareOsteoarthritis of the Knees / Primary Knee Osteoarthritis1
4CompletedTreatmentEndometriosis1
4Not Yet RecruitingTreatmentAcute Pancreatitis (AP) / Gastrointestinal Diseases1
Not AvailableCompletedPreventionEndothelial Disfunction / Lipid Metabolism Disorders / Vascular System Injuries1
Not AvailableCompletedTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableUnknown StatusNot AvailableEye Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)254 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0688 mg/mLALOGPS
logP2.57ALOGPS
logP3.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)-6.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity67.46 m3·mol-1ChemAxon
Polarizability24.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.59
Caco-2 permeable+0.8915
P-glycoprotein substrateNon-substrate0.6501
P-glycoprotein inhibitor INon-inhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.9612
Renal organic cation transporterNon-inhibitor0.8634
CYP450 2C9 substrateNon-substrate0.7519
CYP450 2D6 substrateNon-substrate0.9288
CYP450 3A4 substrateNon-substrate0.7143
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.7068
CYP450 2D6 inhibitorNon-inhibitor0.9226
CYP450 2C19 inhibitorInhibitor0.8052
CYP450 3A4 inhibitorInhibitor0.7539
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8559
Ames testNon AMES toxic0.8407
CarcinogenicityNon-carcinogens0.7825
BiodegradationNot ready biodegradable0.8499
Rat acute toxicity1.6791 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8933
hERG inhibition (predictor II)Non-inhibitor0.9462
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0006-1853900000-4919511a11ec24935434
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-0006-1853900000-4919511a11ec24935434
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 50V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 60V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 40V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF , NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 50V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 60V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 20V, NegativeLC-MS/MSNot Available
MS/MS Spectrum - ESI-TOF 40V, NegativeLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-0090000000-d9def7cee71fb7a40786
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004r-0970000000-f8c7ca07f27bfc1b8bda
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0006-0900000000-b1333b06db343c38f529
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014l-0900000000-c856c7fa9653868e5785
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004r-0950000000-8e44b9aa58ac75282058
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000f-0900000000-2b750fcfd933ce8809f2
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-014i-0900000000-79bf3bfcbb7bcdd0ffd2
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-014i-0900000000-9340e3fe04d435cf8475
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-004i-0590000000-4a9b53d6aad6ed8189d2
LC-MS/MS Spectrum - LC-ESI-TOF , negativeLC-MS/MSsplash10-00kf-0900000000-b0f6bf3388d96335d77e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0390000000-f19a725fa516c1ccd06d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4r-1900000000-12ac653b70e86d051e9a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4l-3900000000-cddc9dc871ae0131587d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aov-4900000000-085c30542d4dbecc9a30
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0390000000-f8caace8d6c937282e65
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052r-1900000000-d06e6e1c144b2d48b364
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aou-3900000000-bb14be278509155e8ce6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-016r-8900000000-7a10869ce89fa2c7828f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0290000000-9742e3e8991c1c0c270d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002r-0940000000-07826509d63ca5c6ed72
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0910000000-2cac03dc9e9b045fdf23
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002r-0940000000-fb2be32a94602011c1b2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0920000000-4b294faea28304389dcf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0910000000-7cfbcea1e1b612e05a02
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0910000000-93888a6f43e37bc70298
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-1890000000-5a90c0c5508894cb16af
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-2910000000-e0183692948660939c19
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ar9-0910000000-b498b69c984c5f85498e

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Styrenes / Resorcinols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Stilbene / Styrene / Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Benzenoid / Monocyclic benzene moiety / Organic oxygen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
resveratrol (CHEBI:45713) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes, Stilbenes (C03582) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes (LMPK13090005)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nadph dehydrogenase (quinone) activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
Gene Name
NQO2
Uniprot ID
P16083
Uniprot Name
Ribosyldihydronicotinamide dehydrogenase [quinone]
Molecular Weight
25918.4 Da
References
  1. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry. 2004 Sep 14;43(36):11417-26. [PubMed:15350128]
  2. Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM: Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun. 2004 Oct 22;323(3):743-9. [PubMed:15381063]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated ser...
Gene Name
CSNK2A1
Uniprot ID
P68400
Uniprot Name
Casein kinase II subunit alpha
Molecular Weight
45143.25 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function
Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. Converts ...
Gene Name
ALOX15
Uniprot ID
P16050
Uniprot Name
Arachidonate 15-lipoxygenase
Molecular Weight
74803.795 Da
References
  1. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34. [PubMed:10491155]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem. 1999 Oct 1;265(1):27-34. [PubMed:10491155]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription regulatory region dna binding
Specific Function
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
Gene Name
AHR
Uniprot ID
P35869
Uniprot Name
Aryl hydrocarbon receptor
Molecular Weight
96146.705 Da
References
  1. de Medina P, Casper R, Savouret JF, Poirot M: Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators. J Med Chem. 2005 Jan 13;48(1):287-91. [PubMed:15634023]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Together with PI4K2A and the type III PI4Ks (PIK4CA and PIK4CB) it contributes to the overall PI4-kinase activity of the cell. This contribution may be especially significant in plasma membrane, endosomal and Golgi compartments. The phosphorylation of phosphatidylinositol (PI) to PI4P is the first committed step in the generation of phosphatidylinositol 4,5-bisphosphate (PIP2), a precursor of the second messenger inositol 1,4,5-trisphosphate (InsP3). Contributes to the production of InsP3 in stimulated cells and is likely to be involved in the regulation of vesicular trafficking.
Specific Function
1-phosphatidylinositol 4-kinase activity
Gene Name
PI4K2B
Uniprot ID
Q8TCG2
Uniprot Name
Phosphatidylinositol 4-kinase type 2-beta
Molecular Weight
54743.71 Da
References
  1. Srivastava R, Ratheesh A, Gude RK, Rao KV, Panda D, Subrahmanyam G: Resveratrol inhibits type II phosphatidylinositol 4-kinase: a key component in pathways of phosphoinositide turn over. Biochem Pharmacol. 2005 Oct 1;70(7):1048-55. [PubMed:16102733]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Integrin alpha-5/beta-1 is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. ITGA5:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGA5:ITGB1 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881).
Specific Function
Epidermal growth factor receptor binding
Gene Name
ITGA5
Uniprot ID
P08648
Uniprot Name
Integrin alpha-5
Molecular Weight
114535.52 Da
References
  1. Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY: Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer. 2013 Dec;4(6):335-42. doi: 10.1007/s12672-013-0156-8. Epub 2013 Aug 14. [PubMed:23943159]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Wil...
Gene Name
ITGB3
Uniprot ID
P05106
Uniprot Name
Integrin beta-3
Molecular Weight
87056.975 Da
References
  1. Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY: Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer. 2013 Dec;4(6):335-42. doi: 10.1007/s12672-013-0156-8. Epub 2013 Aug 14. [PubMed:23943159]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transition metal ion binding
Specific Function
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
Gene Name
APP
Uniprot ID
P05067
Uniprot Name
Amyloid beta A4 protein
Molecular Weight
86942.715 Da
References
  1. Ahn JS, Lee JH, Kim JH, Paik SR: Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol. Anal Biochem. 2007 Aug 15;367(2):259-65. Epub 2007 May 26. [PubMed:17597573]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
SNCA
Uniprot ID
P37840
Uniprot Name
Alpha-synuclein
Molecular Weight
14460.155 Da
References
  1. Ahn JS, Lee JH, Kim JH, Paik SR: Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol. Anal Biochem. 2007 Aug 15;367(2):259-65. Epub 2007 May 26. [PubMed:17597573]
Details
13. Estrogen receptor alpha
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, Forti L, Stivala LA, Iacopetta D, Dolce V, Ando S, Pezzi V, Maggiolini M: Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol Nutr Food Res. 2009 Jul;53(7):845-58. doi: 10.1002/mnfr.200800331. [PubMed:19496085]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Organic cyclic compound binding
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1A
Uniprot ID
P48039
Uniprot Name
Melatonin receptor type 1A
Molecular Weight
39374.315 Da
References
  1. Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, Leclerc V, Yous S, Delagrange P, Boutin JA: Old and new inhibitors of quinone reductase 2. Chem Biol Interact. 2010 Jul 30;186(2):103-9. doi: 10.1016/j.cbi.2010.04.006. Epub 2010 May 4. [PubMed:20399199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Melatonin receptor activity
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1B
Uniprot ID
P49286
Uniprot Name
Melatonin receptor type 1B
Molecular Weight
40187.895 Da
References
  1. Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, Leclerc V, Yous S, Delagrange P, Boutin JA: Old and new inhibitors of quinone reductase 2. Chem Biol Interact. 2010 Jul 30;186(2):103-9. doi: 10.1016/j.cbi.2010.04.006. Epub 2010 May 4. [PubMed:20399199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Carbohydrate binding
Specific Function
Not Available
Gene Name
CLEC14A
Uniprot ID
Q86T13
Uniprot Name
C-type lectin domain family 14 member A
Molecular Weight
51635.005 Da
References
  1. Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C: Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet. 2010 Nov 15;19(22):4319-29. doi: 10.1093/hmg/ddq354. Epub 2010 Aug 20. [PubMed:20729295]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xenobiotic transporter activity
Specific Function
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
Gene Name
SLC2A1
Uniprot ID
P11166
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 1
Molecular Weight
54083.325 Da
References
  1. Salas M, Obando P, Ojeda L, Ojeda P, Perez A, Vargas-Uribe M, Rivas CI, Vera JC, Reyes AM: Resolution of the direct interaction with and inhibition of the human GLUT1 hexose transporter by resveratrol from its effect on glucose accumulation. Am J Physiol Cell Physiol. 2013 Jul 1;305(1):C90-9. doi: 10.1152/ajpcell.00387.2012. Epub 2013 Apr 24. [PubMed:23615963]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-e2 9-reductase activity
Specific Function
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. ...
Gene Name
CBR1
Uniprot ID
P16152
Uniprot Name
Carbonyl reductase [NADPH] 1
Molecular Weight
30374.73 Da
References
  1. Ito Y, Mitani T, Harada N, Isayama A, Tanimori S, Takenaka S, Nakano Y, Inui H, Yamaji R: Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene. J Nutr Sci Vitaminol (Tokyo). 2013;59(4):358-64. [PubMed:24064738]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17. [PubMed:24454499]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T, Shirasawa T: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study. Evid Based Complement Alternat Med. 2013;2013:589169. doi: 10.1155/2013/589169. Epub 2013 Dec 17. [PubMed:24454499]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein serine/threonine/tyrosine kinase activity
Specific Function
AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, ...
Gene Name
AKT1
Uniprot ID
P31749
Uniprot Name
RAC-alpha serine/threonine-protein kinase
Molecular Weight
55686.035 Da
References
  1. Hsieh TC, Lin CY, Bennett DJ, Wu E, Wu JM: Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS One. 2014 Jun 26;9(6):e101070. doi: 10.1371/journal.pone.0101070. eCollection 2014. [PubMed:24968355]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Binds to the dendritic targeting element and may play a role in mRNA trafficking (By similarity). Part of a ternary complex that binds to the downstream control sequence (DCS) of the pre-mRNA. Mediates exon inclusion in transcripts that are subject to tissue-specific alternative splicing. May interact with single-stranded DNA from the far-upstream element (FUSE). May activate gene expression. Also involved in degradation of inherently unstable mRNAs that contain AU-rich elements (AREs) in their 3'-UTR, possibly by recruiting degradation machinery to ARE-containing mRNAs.
Specific Function
Dna binding
Gene Name
KHSRP
Uniprot ID
Q92945
Uniprot Name
Far upstream element-binding protein 2
Molecular Weight
73115.16 Da
References
  1. Bollmann F, Art J, Henke J, Schrick K, Besche V, Bros M, Li H, Siuda D, Handler N, Bauer F, Erker T, Behnke F, Monch B, Hardle L, Hoffmann M, Chen CY, Forstermann U, Dirsch VM, Werz O, Kleinert H, Pautz A: Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity. Nucleic Acids Res. 2014 Nov 10;42(20):12555-69. doi: 10.1093/nar/gku1033. Epub 2014 Oct 28. [PubMed:25352548]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tyrosine-trna ligase activity
Specific Function
Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
Gene Name
YARS
Uniprot ID
P54577
Uniprot Name
Tyrosine--tRNA ligase, cytoplasmic
Molecular Weight
59143.025 Da
References
  1. Sajish M, Schimmel P: A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature. 2015 Mar 19;519(7543):370-3. doi: 10.1038/nature14028. Epub 2014 Dec 22. [PubMed:25533949]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085]
  2. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
  2. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085]
Details
3. Cytochrome P450 1B1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871]
Details
4. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS: Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep;3(9):1168-75. doi: 10.1158/1940-6207.CAPR-09-0155. Epub 2010 Aug 17. [PubMed:20716633]
  2. Piver B, Berthou F, Dreano Y, Lucas D: Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett. 2001 Dec 15;125(1-3):83-91. [PubMed:11701226]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name
TTR
Uniprot ID
P02766
Uniprot Name
Transthyretin
Molecular Weight
15886.88 Da
References
  1. Commodari F, Khiat A, Ibrahimi S, Brizius AR, Kalkstein N: Comparison of the phytoestrogen trans-resveratrol (3,4',5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn Reson Chem. 2005 Jul;43(7):567-72. [PubMed:15809979]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lu Z, Zhang Y, Liu H, Yuan J, Zheng Z, Zou G: Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. J Fluoresc. 2007 Sep;17(5):580-7. Epub 2007 Jun 28. [PubMed:17597382]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:17